 |
Polyethylene glycol-modified uricase |
|---|---|
| Trade Name | |
| Orphan Indication | Hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated |
| USA Market Approval | USA |
| USA Designation Date | 2005-06-06 00:00:00 |
| Sponsor | EnzymeRx, LLC;17 Arcadian Avenue, Suite 104;Paramus, New Jersey, 07652 |
